<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306409</url>
  </required_header>
  <id_info>
    <org_study_id>362/09</org_study_id>
    <nct_id>NCT01306409</nct_id>
  </id_info>
  <brief_title>Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)</brief_title>
  <official_title>Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gain information on reticulocyte neocytolysis in patients&#xD;
      treated with ESA with regard to different types of ESA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reticulocyte count on day 7</measure>
    <time_frame>day 7</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Renal Anemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential application of different ESA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cera, darbepoetin, epoetin-beta</intervention_name>
    <description>Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESA</intervention_name>
    <description>Sequential application of three different ESA</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  age &gt; 18 years, dialysis dependent chronic renal failure&#xD;
&#xD;
          -  hemodialysis three times a week&#xD;
&#xD;
          -  Kt/V &gt; 1,2 od URR &gt; 65%&#xD;
&#xD;
          -  hemoglobin between 11 and 13 g/dl within the last 2 months&#xD;
&#xD;
          -  hemoglobin change +/- 1g/dl within the last 4 weeks&#xD;
&#xD;
          -  ESA for at least 8 weeks&#xD;
&#xD;
          -  Ferritin &gt; 300 ng/ml and Tsat &gt; 25%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant bleeding in the last 8 weeks&#xD;
&#xD;
          -  blood transfusion within the last 8 weeks&#xD;
&#xD;
          -  hemoglobin disorder&#xD;
&#xD;
          -  hemolysis&#xD;
&#xD;
          -  Malignant disease&#xD;
&#xD;
          -  Significant inflammation&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  CRP &gt; 30 mg/l&#xD;
&#xD;
          -  Temporary vascular dialysis access&#xD;
&#xD;
          -  Vitamin B12 deficiency&#xD;
&#xD;
          -  Folic acid deficiency&#xD;
&#xD;
          -  Not controlled hyperparathyroidism&#xD;
&#xD;
          -  Not controlled hypertension&#xD;
&#xD;
          -  Epilepsia within thze last 6 months&#xD;
&#xD;
          -  Thrombocyte count &gt; 500 x 10^9 /l&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Dickenmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplantation immunology and nephrology, unversity hospital Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology and Transplantaton Immunology</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>October 18, 2011</last_update_submitted>
  <last_update_submitted_qc>October 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

